Laboratory Corporation of America Holdings (LH) Shares Sold by Dixon Hubard Feinour & Brown Inc. VA

Dixon Hubard Feinour & Brown Inc. VA decreased its holdings in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 2.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,833 shares of the medical research company’s stock after selling 1,015 shares during the quarter. Laboratory Corporation of America comprises approximately 1.6% of Dixon Hubard Feinour & Brown Inc. VA’s holdings, making the stock its 19th biggest holding. Dixon Hubard Feinour & Brown Inc. VA’s holdings in Laboratory Corporation of America were worth $5,561,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of LH. Acrospire Investment Management LLC lifted its holdings in Laboratory Corporation of America by 16.5% in the 2nd quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock worth $109,000 after buying an additional 100 shares in the last quarter. Sun Life Financial INC lifted its holdings in Laboratory Corporation of America by 9,200.0% in the 2nd quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock worth $115,000 after buying an additional 736 shares in the last quarter. IFP Advisors Inc lifted its holdings in Laboratory Corporation of America by 83.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock worth $177,000 after buying an additional 523 shares in the last quarter. Hourglass Capital LLC acquired a new position in Laboratory Corporation of America in the 2nd quarter worth $200,000. Finally, Teacher Retirement System of Texas acquired a new position in Laboratory Corporation of America in the 3rd quarter worth $210,000. Institutional investors and hedge funds own 91.45% of the company’s stock.

In other Laboratory Corporation of America news, Director Dwight Gary Gilliland sold 971 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $153.52, for a total value of $149,067.92. Following the completion of the transaction, the director now owns 3,501 shares in the company, valued at approximately $537,473.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.90% of the stock is owned by corporate insiders.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at $155.26 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.75 and a current ratio of 1.89. Laboratory Corporation of America Holdings has a 1 year low of $125.50 and a 1 year high of $164.22. The firm has a market cap of $15,801.40, a PE ratio of 16.69, a P/E/G ratio of 1.65 and a beta of 0.87.

Laboratory Corporation of America (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.08. Laboratory Corporation of America had a net margin of 7.40% and a return on equity of 16.75%. The business had revenue of $2.60 billion during the quarter, compared to the consensus estimate of $2.55 billion. During the same quarter in the prior year, the firm earned $2.25 EPS. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. research analysts expect that Laboratory Corporation of America Holdings will post 9.52 earnings per share for the current year.

A number of brokerages have recently issued reports on LH. ValuEngine lowered shares of Laboratory Corporation of America from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Robert W. Baird restated a “hold” rating and issued a $166.00 target price on shares of Laboratory Corporation of America in a research note on Tuesday, October 17th. Zacks Investment Research lowered shares of Laboratory Corporation of America from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Barclays upped their target price on shares of Laboratory Corporation of America from $183.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, October 26th. Finally, Mizuho set a $165.00 target price on shares of Laboratory Corporation of America and gave the company a “neutral” rating in a research note on Friday, December 1st. Six investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $170.92.

WARNING: “Laboratory Corporation of America Holdings (LH) Shares Sold by Dixon Hubard Feinour & Brown Inc. VA” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/08/dixon-hubard-feinour-brown-inc-va-sells-1015-shares-of-laboratory-corporation-of-america-holdings-lh.html.

Laboratory Corporation of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply